336 Association of Tranexamic Acid With Blood Loss and Transfusion in Adult Spinal Deformity Surgery: Emulated Target Trial Analysis

View at publisher Summarise with VIRAT
Authors: Syed I. Khalid, Elie Massaad, John D. Arena, Yohannes G. Ghenbot, Mert Marcel Dagli, Joshua L. Golubovsky, Dominick Macaluso, Neil R. Malhotra, Zarina Sultana Ali, Brendan F. Judy, Jang Won Yoon, David Casper
+5 more Amrit S. Khalsa, William Charles Welch, Vincent M. Arlet, Ali Ozturk, John H. Shin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Tranexamic acid (TXA) is increasingly used in adult spinal deformity surgeries to minimize blood loss and the necessity for transfusions. METHODS: We conducted a retrospective cohort study involving 641 adults (aged 18 years and older) who underwent elective spinal deformity surgery at a tertiary academic center from July 2013 to December 2021. Patients were categorized based on their TXA regimen (no TXA, bolus-only, infusion-only, or combined bolus and infusion). The outcomes evaluated included estimated blood loss (EBL), the incidence and volume of transfusions, operative duration, postoperative hemoglobin levels on days 1–3, and 90-day thromboembolic events. We employed overlap propensity-score weighting to control for baseline differences. RESULTS: Among 641 adults (mean age 59.9 years; 35.3% male), 268 (41.8%) received TXA (bolus-only 23.9%, infusion-only 28.7%, combined 47.4%), with a median total dose of 21.8 mg/kg (IQR, 15.5–38.3). TXA use reduced intraoperative blood loss by 129 mL (9.7%). The overlap-weighted risk of any allogeneic transfusion was lower with TXA (73.8% vs. 79.4%; RR, 0.51; 95% CI, 0.21–1.26), with no significant change in transfusion volume (–0.11 log-units; 95% CI, –0.25 to 0.02). TXA preserved postoperative hemoglobin (mean Δ 0.43 g/dL [95% CI, 0.19–0.68] at POD 2; 0.42 g/dL [0.18–0.66] at POD 3). Operative time was similar (mean difference 7.7 min; 95% CI, –18.9 to 34.3). There was no increase in 90-day deep vein thrombosis (RR, 0.77; 95% CI, 0.36–1.68) or pulmonary embolism (RR, 0.88; 95% CI, 0.52–1.50) events. Additionally, there was no increase in 90-day cardiovascular events (RR, 0.91; 95% CI, 0.70–1.18), surgical site infection (RR, 1.36; 95% CI, 0.09–21.59), or any complication (RR, 1.06; 95% CI, 0.91–1.23). Dose-response safety analyses, categorizing total TXA into 40 mg/kg, revealed no dose-dependent increase in complications. CONCLUSIONS: Intraoperative TXA, whether administered as a bolus, infusion, or combined regimen, was associated with a significant reduction in blood loss, preservation of postoperative hemoglobin levels, and a non-significant trend toward fewer allogeneic transfusions, without prolonging operative time or increasing 90-day thromboembolic complications. These real-world data affirm TXA’s safety and efficacy as a core component of multimodal blood conservation in major spine surgery and underscore the need for future prospective trials to optimize dosing and administration protocols.

Fields of Study & Subjects

Blood transfusion and management Trauma Hemostasis Coagulopathy Resuscitation Hemostasis and retained surgical items

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
89–89
Publication date
26 March 2026
Language
EN